1. Home
  2. NFE vs AKBA Comparison

NFE vs AKBA Comparison

Compare NFE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NFE
  • AKBA
  • Stock Information
  • Founded
  • NFE 2014
  • AKBA 2007
  • Country
  • NFE United States
  • AKBA United States
  • Employees
  • NFE N/A
  • AKBA N/A
  • Industry
  • NFE Oil/Gas Transmission
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NFE Utilities
  • AKBA Health Care
  • Exchange
  • NFE Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • NFE 773.2M
  • AKBA 861.7M
  • IPO Year
  • NFE 2019
  • AKBA 2014
  • Fundamental
  • Price
  • NFE $2.31
  • AKBA $3.25
  • Analyst Decision
  • NFE Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • NFE 6
  • AKBA 5
  • Target Price
  • NFE $8.92
  • AKBA $6.90
  • AVG Volume (30 Days)
  • NFE 9.8M
  • AKBA 4.0M
  • Earning Date
  • NFE 08-26-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • NFE N/A
  • AKBA N/A
  • EPS Growth
  • NFE N/A
  • AKBA N/A
  • EPS
  • NFE N/A
  • AKBA N/A
  • Revenue
  • NFE $2,127,808,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • NFE $7.43
  • AKBA $27.95
  • Revenue Next Year
  • NFE $8.38
  • AKBA $43.88
  • P/E Ratio
  • NFE N/A
  • AKBA N/A
  • Revenue Growth
  • NFE N/A
  • AKBA 16.75
  • 52 Week Low
  • NFE $2.01
  • AKBA $1.24
  • 52 Week High
  • NFE $16.66
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • NFE 36.40
  • AKBA 40.09
  • Support Level
  • NFE $2.27
  • AKBA $2.92
  • Resistance Level
  • NFE $3.52
  • AKBA $3.44
  • Average True Range (ATR)
  • NFE 0.34
  • AKBA 0.17
  • MACD
  • NFE -0.10
  • AKBA -0.05
  • Stochastic Oscillator
  • NFE 2.17
  • AKBA 37.08

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: